AbbVie loses patent plea for Hep C drug
New Delhi: The Indian Patent Office has refused to grant a secondary patent to AbbVie for its blockbuster Hepatitis C drug combination glecaprevir/pibrentasvir, sold globally under the brand name Maviret.…
New Delhi: The Indian Patent Office has refused to grant a secondary patent to AbbVie for its blockbuster Hepatitis C drug combination glecaprevir/pibrentasvir, sold globally under the brand name Maviret.…





